Search research articles
Contact Us
Filters
Showing results (461-470 of 545) with videos related to
Page
of 55
Sort By:
Dermatitis : Contact, Atopic, Occupational, Drug
|
January 14, 2022
Shoe Allergens: A Retrospective Analysis of Cross-sectional Data From the North American Contact Dermatitis Group, 2005-2018
Amber Reck Atwater, Raina Bembry, Cynthia L Green, et al.
Dermatitis : Contact, Atopic, Occupational, Drug
|
September 27, 2021
Patch Testing to Ethylhexylglycerin: The North American Contact Dermatitis Group Experience, 2013-2018
Erin M Warshaw, Michele Buonomo, Howard I Maibach, et al.
Dermatitis : Contact, Atopic, Occupational, Drug
|
March 6, 2021
Patch Testing to Methyldibromoglutaronitrile/Phenoxyethanol: North American Contact Dermatitis Group Experience, 1994-2018
Erin M Warshaw, Michele Buonomo, Joel G DeKoven, et al.
The New England Journal of Medicine
|
March 24, 2021
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis
Thomas Bieber, Eric L Simpson, Jonathan I Silverberg, et al.
Journal of the American Academy of Dermatology
|
August 8, 2022
Hand and foot dermatitis in patients referred for patch testing: Analysis of North American Contact Dermatitis Group Data, 2001-2018
Jonathan I Silverberg, Nisha Patel, Erin M Warshaw, et al.
Journal of the American Academy of Dermatology
|
August 20, 2021
Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial
Andrew Blauvelt, Jonathan I Silverberg, Charles W Lynde, et al.
American Journal of Clinical Dermatology
|
March 26, 2024
Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2)
Jonathan I Silverberg, Melinda J Gooderham, Amy S Paller, et al.
Dermatitis : Contact, Atopic, Occupational, Drug
|
July 9, 2021
Contact Allergy in Canada Versus United States: Analysis of the North American Contact Dermatitis Group Data 2005-2016
Amber Reck Atwater, Jordan Maxwell Ward, Beiyu Liu, et al.
Contact Dermatitis
|
July 8, 2022
Patch testing with cobalt in children and adolescents: North American contact dermatitis group experience, 2001-2018
Jonathan I Silverberg, Nisha Patel, Erin M Warshaw, et al.
Journal of the American Academy of Dermatology
|
February 18, 2021
Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)
Eric L Simpson, Seth Forman, Jonathan I Silverberg, et al.
Page
of 55
Search research articles
Search
Showing results (461-470 of 545) with videos related to
Sort By:
Page
of 55
Dermatitis : Contact, Atopic, Occupational, Drug
|
January 14, 2022
Shoe Allergens: A Retrospective Analysis of Cross-sectional Data From the North American Contact Dermatitis Group, 2005-2018
Amber Reck Atwater, Raina Bembry, Cynthia L Green, et al.
Dermatitis : Contact, Atopic, Occupational, Drug
|
September 27, 2021
Patch Testing to Ethylhexylglycerin: The North American Contact Dermatitis Group Experience, 2013-2018
Erin M Warshaw, Michele Buonomo, Howard I Maibach, et al.
Dermatitis : Contact, Atopic, Occupational, Drug
|
March 6, 2021
Patch Testing to Methyldibromoglutaronitrile/Phenoxyethanol: North American Contact Dermatitis Group Experience, 1994-2018
Erin M Warshaw, Michele Buonomo, Joel G DeKoven, et al.
The New England Journal of Medicine
|
March 24, 2021
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis
Thomas Bieber, Eric L Simpson, Jonathan I Silverberg, et al.
Journal of the American Academy of Dermatology
|
August 8, 2022
Hand and foot dermatitis in patients referred for patch testing: Analysis of North American Contact Dermatitis Group Data, 2001-2018
Jonathan I Silverberg, Nisha Patel, Erin M Warshaw, et al.
Journal of the American Academy of Dermatology
|
August 20, 2021
Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial
Andrew Blauvelt, Jonathan I Silverberg, Charles W Lynde, et al.
American Journal of Clinical Dermatology
|
March 26, 2024
Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2)
Jonathan I Silverberg, Melinda J Gooderham, Amy S Paller, et al.
Dermatitis : Contact, Atopic, Occupational, Drug
|
July 9, 2021
Contact Allergy in Canada Versus United States: Analysis of the North American Contact Dermatitis Group Data 2005-2016
Amber Reck Atwater, Jordan Maxwell Ward, Beiyu Liu, et al.
Contact Dermatitis
|
July 8, 2022
Patch testing with cobalt in children and adolescents: North American contact dermatitis group experience, 2001-2018
Jonathan I Silverberg, Nisha Patel, Erin M Warshaw, et al.
Journal of the American Academy of Dermatology
|
February 18, 2021
Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)
Eric L Simpson, Seth Forman, Jonathan I Silverberg, et al.
Page
of 55